High-specific-activity-(131)I-MIBG versus (177)Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma Review

   


Authors: Jha, A.; Taïeb, D.; Carrasquillo, J. A.; Pryma, D. A.; Patel, M.; Millo, C.; de Herder, W. W.; Del Rivero, J.; Crona, J.; Shulkin, B. L.; Virgolini, I.; Chen, A. P.; Mittal, B. R.; Basu, S.; Dillon, J. S.; Hope, T. A.; Aparici, C. M.; Iagaru, A. H.; Hicks, R. J.; Avram, A. M.; Strosberg, J. R.; Civelek, A. C.; Lin, F. I.; Pandit-Taskar, N.; Pacak, K.
Review Title: High-specific-activity-(131)I-MIBG versus (177)Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma
Abstract: Targeted radionuclide therapies (TRT) using 131I-metaiodobenzylguanidine (131I-MIBG) and peptide receptor radionuclide therapy (177Lu or 90Y) represent several of the therapeutic options in the management of metastatic/inoperable pheochromocytoma/paraganglioma. Recently, high-specific-activity-131I-MIBG therapy was approved by the FDA and both 177Lu-DOTATATE and 131I-MIBG therapy were recommended by the National Comprehensive Cancer Network guidelines for the treatment of metastatic pheochromocytoma/paraganglioma. However, a clinical dilemma often arises in the selection of TRT, especially when a patient can be treated with either type of therapy based on eligibility by MIBG and somatostatin receptor imaging. To address this problem, we assembled a group of international experts, including oncologists, endocrinologists, and nuclear medicine physicians, with substantial experience in treating neuroendocrine tumors with TRTs to develop consensus and provide expert recommendations and perspectives on how to select between these two therapeutic options for metastatic/inoperable pheochromocytoma/paraganglioma. This article aims to summarize the survival outcomes of the available TRTs; discuss personalized treatment strategies based on functional imaging scans; address practical issues, including regulatory approvals; and compare toxicities and risk factors across treatments. Furthermore, it discusses the emerging TRTs. © 2021 American Association for Cancer Research.
Journal Title: Clinical Cancer Research
Volume: 27
Issue: 11
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2021-06-01
Start Page: 2989
End Page: 2995
Language: English
DOI: 10.1158/1078-0432.Ccr-20-3703
PUBMED: 33685867
PROVIDER: scopus
PMCID: PMC8172462
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107009092&doi=10.1158%2f1078-0432.CCR-20-3703&partnerID=40&md5=901fa6a62e24a13f29fa65eedf972bbe
Notes: Review -- Export Date: 1 July 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Neeta Pandit-Taskar
    342 Pandit-Taskar
  2. Jorge Carrasquillo
    140 Carrasquillo
Related MSK Work